Zurich-based Rivia raises €13M to expand its agentic AI platform for biotech clinical trials, building on a €3M seed in 2024.
Investigator-initiated trials are uniquely unsuited to a patchwork of Google Drive folders, Excel worksheets, and consumer-grade software. Industry sponsors deploy full ...
Felicione is an independent clinical research scientist and principal investigator. Walk into any drugstore, natural market, or Costco and you’ll find a dazzling array of supplements promising ...
The pseudomonal infections clinical trial analysis report delivers important insights into ongoing research of 10+ pipeline ...
New randomized controlled trial to evaluate dose-dependent effects of oral THC on anxiety and stress using Avicanna’s proprietary capsules ...
The Decentralized Clinical Trials market, valued at USD 8.87 billion in 2024, is expected to register revenue CAGR of 10.2%.Request free copy of this report: 05, 2026- Growing demand for ...
The fifth stock on our list of best investment stocks is Veeva Systems Inc. (NYSE:VEEV). TheFly reported on February 20 that UBS reduced its price target on VEEV to $200 from $280 while maintaining a ...
The newly introduced AI-powered study build engine marks the first phase of ClinCapture's broader intelligent trial roadmap. By automating protocol translation, Captivate establishes a foundation for ...
Earlybird leads round as the startup builds a reusable intelligence layer to unify fragmented trial data and enable AI-driven workflows ...
Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet ...
Morning Overview on MSN
ARPA-H is building clinical AI agents designed for FDA authorization and trials
The Advanced Research Projects Agency for Health, an agency within the U.S. Department of Health and Human Services, published a new program on January 13, 2026, with an ambitious target: building the ...
T Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional decline, reduced risk of ALS-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results